NCT05332340View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics (PK) Evaluation of BZ371A, Topically Administered

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 16, 2022

Primary Completion Date

November 30, 2022

Study Completion Date

November 30, 2022

Conditions
Erectile Dysfunction Following Radical ProstatectomyErectile DysfunctionProstate CancerRadical Prostatectomy
Interventions
DRUG

BZ371A

Single dose topical administration of 1.5 mL with a concentration of 5 mg/mL of BZ371A.

Trial Locations (1)

Unknown

Azidus Brasil Pesquisa Científica e Desenvolvimento, Valinhos

Sponsors
All Listed Sponsors
collaborator

Azidus Brasil Scientific Research and Development Ltda

OTHER

lead

Biozeus Biopharmaceutical S.A.

INDUSTRY